Skip to content

US · SION · BIOTECHNOLOGY

Sionna Therapeutics, Inc. (SION) intrinsic value and stock valuation

$2.83as of 2026-11-21 · Mkt cap 2.3B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sionna Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values SION with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SION’s statements →

Sionna Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 sionnatx.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-75.27M
20222025
Free cash flow
-$-66.67M
20222025
Total equity
$306.8M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-88.98M-$-70.56M-$-50.33M-$-41.37M
Net income-$-75.27M-$-61.69M-$-47.26M-$-40.24M
EPSd-$-1.88M-$-1.4M-$-1.07M-$-912.06K
Operating cash flow-$-66.3M-$-52.79M-$-43.7M-$-36.07M
Capital expenditure-$-380K-$-30K-$-1.12M-$-1.87M
Free cash flow-$-66.67M-$-52.81M-$-44.81M-$-37.94M
Total assets$326M$185.8M$52M$87.4M
Total debt$8.68M$9.75M$10.5M$0.00
Net debt-$-49.77M-$-28.04M-$-28.04M-$-54.84M
Total equity$306.8M-$-163.71M-$-114.88M-$-69.92M
Cash and short-term investments$235.9M$147.5M$38.5M$82.6M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$650K$670K$0.00$0.00
Gross profit-$-650K-$-670K$0.00$0.00
Research and development expenses$60.3M$57.3M$40.6M$34.6M
Selling, general and administrative expenses$28.7M$13.3M$9.71M$6.77M
Other expenses-$-650K-$-670K$0.00$0.00
Operating expenses$88.3M$69.9M$50.3M$41.4M
Cost and expenses$89M$70.6M$50.3M$41.4M
Interest income$13.3M$8.17M$2.77M$1.13M
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$650K$670K$580K$120K
Ebitda-$-74.62M-$-61.02M-$-46.68M-$-40.12M
Operating income-$-88.98M-$-70.56M-$-50.33M-$-41.37M
Total other income/expenses, net$13.7M$8.87M$3.07M$1.13M
Income before tax-$-75.27M-$-61.69M-$-47.26M-$-40.24M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-75.27M-$-61.69M-$-47.26M-$-40.24M
Weighted average shares outstanding$40M$44.1M$44.1M$44.1M
Weighted average diluted shares outstanding$40M$44.1M$44.1M$44.1M
Balance sheet
2025202420232022
Cash and short-term investments$235.9M$147.5M$38.5M$82.6M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$241.4M$151M$39.2M$83.8M
Property, plant and equipment, net$9.15M$10.3M$11.7M$2.57M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$74.4M$20.5M$960K$0.00
Total non-current assets$84.5M$34.8M$12.7M$3.54M
Total assets$326M$185.8M$52M$87.4M
Accounts payable$770K$1.19M$720K$560K
Short-term debt$1.27M$1.07M$730K$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$11.7M$10.4M$8.04M$8.25M
Long-term debt$7.41M$8.68M$9.75M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$7.41M$339.1M$158.8M$149M
Capital lease obligations$8.68M$9.75M$10.5M$0.00
Total liabilities$19.1M$349.5M$166.8M$157.3M
Common stock$40K$10K$0.00$0.00
Retained earnings-$-256.35M-$-181.09M-$-119.4M-$-72.14M
Accumulated other comprehensive income (loss)$540K$370K$0.00-$-20K
Total equity$306.8M-$-163.71M-$-114.88M-$-69.92M
Total investments$251.9M$130.3M$960K$27.8M
Total debt$8.68M$9.75M$10.5M$0.00
Net debt-$-49.77M-$-28.04M-$-28.04M-$-54.84M
Cash flow statement
2025202420232022
Net income-$-75.27M-$-61.69M-$-47.26M-$-40.24M
Depreciation and amortization-$-3.05M$670K$580K$120K
Stock-based compensation$12.1M$3.71M$2.26M$1.69M
Change in working capital-$-2.65M-$-3.08M-$-780K$2.76M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-420K$470K$160K-$-1.51M
Net cash provided by operating activities-$-66.3M-$-52.79M-$-43.7M-$-36.07M
Investments in property, plant and equipment-$-380K-$-30K-$-1.12M-$-1.87M
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-118.75M-$-126.91M$27.4M-$-29.26M
Common stock issued$205.7M$179M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$205.7M$179M$30K$110.9M
Net change in cash$20.7M-$-730K-$-16.32M$45.5M
Cash at end of period$59.4M$38.8M$39.5M$55.8M
Operating cash flow-$-66.3M-$-52.79M-$-43.7M-$-36.07M
Capital expenditure-$-380K-$-30K-$-1.12M-$-1.87M
Free cash flow-$-66.67M-$-52.81M-$-44.81M-$-37.94M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sionna Therapeutics, Inc.

        Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.

        CEO
        Michael Cloonan
        Employees
        59
        Beta
        1.32

        Explore

        Frequently asked questions

        What is the intrinsic value of Sionna Therapeutics, Inc. (SION)?

        InvestorsCraft does not currently publish an intrinsic value for SION. How the IC value is calculated.

        Is SION undervalued?

        InvestorsCraft does not publish an undervaluation signal for SION at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.